Journal
SURVEY OF OPHTHALMOLOGY
Volume 66, Issue 4, Pages 572-584Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.survophthal.2020.12.002
Keywords
retinopathy of prematurity; bevacizumab; ranibizumab; lasers; laser therapy
Categories
Ask authors/readers for more resources
In the treatment of retinopathy of prematurity, intravitreal injection (IVI) of antivascular endothelial growth factor agents and laser photocoagulation (LPC) have similar regression rates, but eyes receiving IVI are more likely to require additional treatment and longer time. Eyes receiving IVI required surgical intervention less often compared to LPC, and had lower levels of astigmatism.
We investigate the efficacy and safety of intravitreal injection (IVI) of antivascular endothelial growth factor agents and laser photocoagulation (LPC) for retinopathy of prematurity. We performed a systematic search of Ovid MEDLINE, EMBASE, and Cochrane CENTRAL (2005-2019). Comparative studies reporting on ocular efficacy and/or safety outcomes after IVIs and LPC for retinopathy of prematurity were included. The primary outcome was the regression rate, whereas secondary endpoints included the likelihood of requiring additional treatment, visual and refractive outcomes, and complications. Overall, 777 publications were identified. Twenty-four articles were included, with 1,289 eyes receiving IVI and 2,412 eyes undergoing LPC. There was no significant difference in the regression rate between IVI and LPC (P = 0.68); however, eyes that underwent IVI were associated with a significantly higher likelihood of requiring additional treatment (risk ratio = 2.16, 95% confidence interval (CI) = [1.26, 3.73], P = 0.005) and longer time from treatment to retreatment or recurrence (weighted mean difference = 6.43 weeks, 95% CI = [2.36, 10.51], P = 0.002). Eyes receiving IVI required surgical intervention significantly less often (risk ratio = 0.45, 95% CI = [0.23, 0.89], P = 0.02). Astigmatism was significantly lower after IVI relative to LPC (weighted mean difference = -0.25 D, 95% CI = [-0.45, -0.06], P = 0.01), and there was a lower proportion of emmetropic eyes at last follow-up after LPC (risk
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available